Ofatumumab domestic price

Ofatumumab (Ofatumumab) has been marketed under two different trade names: Arzerra and Kesimpta. Arzerra is used to treat chronic lymphocytic leukemia (CLL), sometimes in combination with other cancer drugs, while Kesimpta is used to treat relapsing forms of multiple sclerosis (including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease) in adults.

Ofatumumab is a fully humanized monoclonal anti CD20 antibody constructed using recombinant DNA technology and designed to selectively target CD20-expressing B cells. Upon cell surface binding, ofatumumab selectively depletes CD20-expressing B cells via antibody-dependent phagocytosis, antibody-dependent cytotoxicity, complement-dependent cytotoxicity, and apoptosis. The exact mechanism by which ofatumumab exerts its clinical efficacy in multiple sclerosis is unknown but may be mediated by a reduction in the number and function of CD20-expressing B cells.

The original drug of ofatumumab has been approved by the State Food and Drug Administration for marketing in China, but it is only used to treat multiple sclerosis. It has also been included in medical insurance and is limited to patients who meet the indications for reimbursement. The price is around tens of thousands of yuan, and the trade name is Quanxinda. The European version of ofatumumab original drug specifications20mg/0.4mL each sold overseas may cost around RMB 16,000 (the price may fluctuate due to the exchange rate). It is expensive and there are currently no generics of ofatumumab. For more drug information and specific prices, please consult a medical consultant.